Biotechnology company Galapagos NV announced plans to allocate up to $500 million independently to support the company's strategic development.

In this funding arrangement, up to $150 million is expected to be allocated specifically for a share repurchase program or distribution of dividends to shareholders, while the remaining portion will be invested in research and development as well as business expansion. This deployment of funds highlights the company's commitment to enhancing financial flexibility while balancing shareholder returns and long-term growth requirements.